Fibrosis Assessment in Myocardial Infarction-associated Ventricular Aneurysm
Assessment of Myocardial Fibrosis by 18F-FAPI/PET-CT in Patients With Myocardial Infarction-associated Ventricular Aneurysm
RenJi Hospital
20 participants
Nov 1, 2024
OBSERVATIONAL
Conditions
Summary
The study will use 18F-FAPI PET/CT to study myocardial fibrosis in patients diagnosed with myocardial infarction-associated ventricular aneurysm (MI-VA). Participants will receive the PET/CT scan during hospital stay, as well as serial echocardiography and telephonic follow-ups. Analysed will focus on the characterization of myocardial fibrosis and its correlations with the clinical prognosis in the patients.
Eligibility
Inclusion Criteria6
- Aged 18-75 years old
- Diagnosed with STEMI or NSTEMI (ACC/AHA guidelines)
- Half male and half female
- Undergo CAG and PCI treatment;
- Receive either echocardiography or CMR to identify a ventricular aneurysm;
- Written informed consent
Exclusion Criteria3
- Patients under the age of 18 years old;
- Patients who are pregnant/breastfeeding;
- Patients who has a previous history of allergy to radio tracers.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
During the hospital stay, participants will receive an 18F FAPI-42 PET/CT scan. 18F FAPI-42 is a new fibroblast activation protein (FAP)-specific tracer used for fibrosis imaging. PET/CT will be performed using the ultra-high-resolution digital PET/CT uEXPLORER (United Imaging, Shanghai, China)
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06994221